GI
ALNY icon

GAMMA Investing’s Alnylam Pharmaceuticals ALNY Stock Holding History

GAMMA Investing’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$226K Sell
917
-20
-2% -$5.09K 0.01% 1237
2026
Q2 		$282K Sell
937
-57
-6% -$17.2K 0.01% 1020
2026
Q1 		$329K Buy
994
+101
+11% +$34.4K 0.02% 795
2025
Q4 		$355K Buy
893
+70
+9% +$31K 0.02% 677
2025
Q3 		$375K Buy
823
+97
+13% +$39.5K 0.02% 610
2025
Q2 		$237K Buy
726
+110
+18% +$30.4K 0.02% 803
2025
Q1 		$166K Buy
616
+77
+14% +$19.8K 0.01% 874
2024
Q4 		$127K Sell
539
-15
-3% -$3.94K 0.01% 945
2024
Q3 		$152K Buy
554
+138
+33% +$35.9K 0.02% 750
2024
Q2 		$101K Buy
416
+205
+97% +$32.4K 0.01% 775
2024
Q1 		$31.5K Sell
211
-59
-22% -$9.84K 0.01% 1331
2023
Q4 		$46.7K Buy
+270
New +$46K 0.01% 932

Other funds holding ALNY

MSV
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
LJHT
Laurie J. Hall Trustee $314M AUM 27.43% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
CPBTD
Central Pacific Bank - Trust Division Honolulu, Hawaii $952M AUM 25.15% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
BFS
Burkett Financial Services Rock Hill, South Carolina $331M AUM 14.93% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return

GAMMA Investing's ALNY Position: Q3 2026 in Review

GAMMA Investing reduced its Alnylam Pharmaceuticals (ALNY) stake by 2.1% in Q3 2026, selling an estimated $5.09K and leaving 917 shares worth $226K. The position accounts for 0.01% of the portfolio, ranked #1237.

GAMMA Investing first reported a position in ALNY in Q4 2023 and has held it in 12 quarters since. The position peaked at $375K in Q3 2025. 19 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • GAMMA Investing held 917 shares of Alnylam Pharmaceuticals worth $226K as of Q3 2026.
  • GAMMA Investing sold 20 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $5.09K.
  • Alnylam Pharmaceuticals made up 0.01% of GAMMA Investing's portfolio in Q3 2026, its #1237 holding.
  • GAMMA Investing first reported a position in Alnylam Pharmaceuticals in Q4 2023 and has held it in 12 quarters since.
  • GAMMA Investing's Alnylam Pharmaceuticals position peaked at $375K in Q3 2025.
  • 19 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.